Recursion (RXRX) reported top-line results of the SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for REC-994 in symptomatic Cerebral Cavernous Malformation patients. REC-994 met primary endpoint of safety and tolerability, showing a similar profile across placebo and both 200mg and 400mg dosage-arms with regard to the frequency and severity of adverse events after 12 months of treatment.

Recursion（RXRX）报告了SYCAMORE试验的主要结果，该试验是REC-994在症状性脑海绵状血管畸形患者中进行的为期12个月的2期随机双盲，安慰剂对照，安全性，耐受性和探索性疗效研究。REC-994符合安全性和耐受性的主要终点，在安慰剂和200mg和400mg剂量组中，治疗12个月后不良事件的频率和严重程度相似。

Recursion plans to present data from the trial at a forthcoming medical conference and intends to submit data for publication in a peer reviewed scientific journal.For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News.

Recursion计划在即将举行的医学会议上提供该试验的数据，并打算将数据提交给同行评审的科学期刊发表。有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股